P
PHIO PHARMACEUTICALS CORP
NASDAQ: PHIO (Phio Pharmaceuticals Corp.)
Last update: 1 hour ago0.985
-0.02 (-1.50%)
| Previous Close | 1.00 |
| Volume | 54,214 |
| Price / Earnings (Forward) | 0.310 |
| Price / Sales | 48.01 |
| Price / Book | 0.940 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -9.02 |
| Current Ratio (MRQ) | 10.58 |
| Operating Cash Flow (TTM) | -6.38 M |
| Levered Free Cash Flow (TTM) | -4.01 M |
| Return on Assets (TTM) | -43.43% |
| Return on Equity (TTM) | -76.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Phio Pharmaceuticals Corp. | Mixed | Mixed |
AIStockmoo Score
-1.4
| Analyst Consensus | NA |
| Insider Activity | 4.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | -2.5 |
| Average | -1.38 |
|
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 15.77% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BITTERMAN ROBERT J | 1.00 | - | 2,000 | 2,000 |
| BRADFORD PATRICIA A | 1.02 | - | 6,500 | 6,630 |
| Aggregate Net Quantity | 8,500 | |||
| Aggregate Net Value ($) | 8,630 | |||
| Aggregate Avg. Buy ($) | 1.01 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BRADFORD PATRICIA A | Director | 24 Sep 2026 | Buy (+) | 6,500 | 1.02 | 6,630 |
| BITTERMAN ROBERT J | Officer | 22 Sep 2026 | Buy (+) | 2,000 | 1.00 | 2,000 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |